Predicting drug response based on gene expression

Critical Reviews in Oncology/Hematology

Volumn 51, Issue 3, 2004, Pages 205-227

  Robert, Jacques ^a   Vekris, Antoine ^a   Pourquier, Philippe ^a   Bonnet, Jacques ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Chemotherapy; Drug resistance; Drug sensitivity; Gene expression profiling; NCI60 panel

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOPLATIN; CHLORAMBUCIL; CHLOROETHYLNITROSOUREA DERIVATIVE; CISPLATIN; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DIHYDROFOLATE REDUCTASE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; INTERLEUKIN 6; INTERLEUKIN 8; IRINOTECAN; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; NITROSOUREA DERIVATIVE; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROTEIN P53; RETROVIRUS VECTOR; TEMOZOLOMIDE; TRABECTEDIN; TRASTUZUMAB; UNINDEXED DRUG;

APOPTOSIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CHINESE HAMSTER; COLON CANCER; CORRELATION ANALYSIS; CYTOTOXICITY; DNA DAMAGE; DNA MICROARRAY; DNA REPAIR; DNA SEQUENCE; DNA SYNTHESIS; DRUG ACTIVATION; DRUG ACTIVITY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TRANSPORT; EXCISION REPAIR; GENE EXPRESSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE SILENCING; GLIOMA; HUMAN; LUNG CANCER; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MELANOMA; MELANOMA CELL; MOLECULAR BIOLOGY; NONHUMAN; ONCOGENE; OVARY CANCER; REVIEW; RNA INTERFERENCE; SERIAL ANALYSIS OF GENE EXPRESSION; STROMA CELL; TUMOR CELL; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS; PROGNOSIS;

EID: 4444266101     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2004.06.002     Document Type: Review

References (221)

1. A.W. Hamburger, and S.E. Salmon Primary bioassay of human tumor stem cells Science 197 1977 461 463
2. D.D. Von Hoff He's not going to talk about in vitro predictive assays again, is he? J. Natl. Cancer Inst. 82 1990 96 101
3. J. Robert Chemosensitivity testing. Prediction of response to anticancer drugs using in vitro assays Electr. J. Oncol. 2 1999 198 210
4. J. Robert Multidrug resistance in oncology: diagnostic and therapeutic approaches Eur. J. Clin. Invest. 29 1999 536 545
5. J.L. Biedler, and H. Riehm Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies Cancer Res. 30 1970 1174 1184
6. A.W. Schrecker, J.A. Mead, N.H. Greenberg, and A. Goldin Dihydrofolate reductase activity of leukemia L1210 during development of methotrexate resistance Biochem. Pharmacol. 20 1971 716 718
7. C. Chen, J.E. Chin, K. Ueda, D.P. Clark, I. Pastan, and M.M. Gottesman Internal duplication and homology with bacterial transport proteins in the MDR1 (P-glycoprotein) gene from multidrug-resistant human cells Cell 47 1986 381 389
8. R.T. Schimke, F.W. Alt, R.E. Kellems, R.J. Kaufman, and J.R. Bertino Amplification of dihydrofolate reductase genes in methotrexate-resistant cultured mouse cells Cold Spring Harb Symp Quant Biol. 42 1978 649 657
9. I.B. Roninson, H.T. Abelson, D.E. Housman, N. Howell, and A. Varshavsky Amplification of specific DNA sequences correlates with multi-drug resistance in Chinese hamster cells Nature 309 1998 626 628
10. S.P. Cole, G. Bhardwaj, J.H. Gerlach, J.E. Mackie, C.E. Grant, and K.C. Almquist Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line Science 258 1992 1650 1653
11. T. Hisano, M. Ono, M. Nakayama, S. Naito, M. Kuwano, and M. Wada Increased expression of T-plastin gene in cisplatin-resistant human cancer cells; identification by mRNA differential display FEBS Lett. 397 1996 101 107
12. Z. Duan, A.J. Feller, H.C. Toh, T. Makastorsis, and M.V. Seiden TRAG-3, a novel gene isolated from a taxol-resistant ovarian carcinoma cell line Gene 229 1999 75 81
13. C. Grottke, K. Mantivill, M. Dietel, D. Schadendorf, and H. Lage Identification of differentially expressed genes in human melanoma cells with acquired resistance to various antineoplastic drug Int. J. Cancer 88 2000 535 546
14. A. Johnsson, I. Teelenberg, Y. Min, J. Hilinski, C. Berg, and S.B. Howell Identification of genes differentially expressed in association with acquired cisplatin resistance Br. J. Cancer 83 2000 1047 1054
15. K. Kudoh, M. Ramanna, R. Ravatn, A.G. Elkahloun, M.L. Bittner, and P.S. Meltzer Monitoring the expression profiles of doxorubicin-induced and doxorubicin resistant cancer cells by cDNA microarray Cancer Res. 60 2000 4161 4166
16. N.J. Turton, D.J. Judah, J. Riley, R. Davies, D. Lipson, and J.A. Styles Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance Oncogene 20 2001 1300 1306
17. G.S. Watts, B.W. Futscher, R. Isett, M. Gleason-Guzman, M.W. Kunkel, and S.E. Salmon cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways J. Pharmacol. Exp. Ther. 299 2001 434 441
18. G. Los, F. Yang, G. Samimi, G. Manorek, I.M. Guerorguieva, and S. Howell Using mRNA expression profiling to determine anticancer drug efficacy Cytometry 47 2002 66 71
19. Z. Duan, A.J. Feller, R.T. Penson, B.A. Chabner, and M.V. Seiden Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin-6, interleukin-8, and monocyte chemotactic protein I in the paclitaxel-resistant phenotype Clin. Cancer Res. 5 1999 3445 3453
20. W.C. Reinhold, H. Kouros-Mehr, K.W. Kohn, A.K. Maunakea, S. Lababidi, and A. Roschke Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping Cancer Res. 63 2003 1000 1011
21. N.M. Verrills, B.J. Walsh, G.S. Cobon, P.G. Hains, and M. Kavallaris Proteome analysis of vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations J. Biol. Chem. 278 2003 45082 45093
22. K. Boon, E.C. Osorio, S.F. Greenhut, C.F. Schaefer, J. Shoemaker, and K. Polyak An anatomy of normal and malignant gene expression Proc. Natl. Acad Sci. U.S.A. 99 2002 11287 11292
23. C.A. Sherman-Baust, A.T. Weeraratna, L.B.A. Rangel, E.S. Pizer, K.R. Cho, and D.R. Schwartz Remodeling the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells Cancer Cell 3 2003 377 386
24. P.M. Hwang, F. Bunz, J. Yu, C. Rago, T.A. Chan, and M.P. Murphy Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells Nat. Med. 7 2001 1111 1117
25. A.V. Gudkov, A.R. Kazarow, R. Thimmapaya, S.A. Axenovich, I.A. Mazo, and I.B. Roninson Cloning mammalian genes by expression selection of genetic suppressor elements: association of kinesine with drug resistance and cell immortalization Proc. Natl. Acad Sci. U.S.A. 91 1994 3744 3748
26. V.V. Levenson, I.A. Davidovich, and I.B. Roninson Pleiotropic resistance to DNA-interactive drugs is associated with increased expression of genes involved in RNA replication, repair, and stress response Cancer Res. 60 2000 5027 5030
27. L. Gros, C. Delaporte, S. Frey, J. Decesse, B.R. de Saint-Vincent, and L. Cavarec Identification of new drug sensitivity genes using genetic suppressor elements: protein arginine N-methyltransferase mediates cell sensitivity to DNA-damaging agents Cancer Res. 63 2003 164 171
28. G. Sanz, L. Mir, and A. Jacquemin-Sablon Bleomycin resistance in mammalian cells expressing a genetic suppressor element derived from the SRPK1 gene Cancer Res. 62 2002 4453 4458
29. J.W. Myers, J.T. Jones, T. Meyer, and J.E. Ferrell Jr. Recombinant dicer efficiently converts large dsRNAs into siRNAs suitable for gene silencing Nat. Biotechnol. 21 2003 324 328
30. D. Shirane, K. Sugao, S. Namiki, M. Tanabe, M. Iino, and K. Hirose Enzymatic production of RNAi libraries from cDNAs Nat. Genet. 36 2004 190 196
31. M. Boutros, A.A. Kiger, S. Armknecht, K. Kerr, M. Hild, and B. Koch Genome-wide RNAi analysis of growth and viability in Drosophila cells Science 303 2004 832 835
32. K. Kohn Molecular interaction map of the mammalian cell cycle control and DNA repair systems Mol. Biol. Cell. 10 1999 2703 2734
33. A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, and D. Vistica Feasibility of a high flux anticancer drug screen using a diverse panel of cultured human tumor cell lines J. Natl. Cancer Inst. 83 1991 757 766
34. J.N. Weinstein, T.G. Myers, P.M. O'Connor, S.H. Friend, A.J. Fornace, and K.W. Kohn An information-intensive approach to the molecular pharmacology of cancer Science 275 1997 343 349
35. K.D. Paull, R.H. Shoemaker, L. Hodes, A. Monks, D.A. Scudiero, and L. Rubinstein Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm J. Natl. Cancer Inst. 81 1989 1088 1092
36. P.M. O'Connor, J. Jackman, I. Bae, T.G. Myers, S. Fan, and M. Mutoh Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents Cancer Res. 57 1997 4285 4300
37. Z. Xu, Z.P. Chen, A. Malapetsa, M. Alaoui-Jamali, J. Bergeron, and A. Monks DNA repair protein levels vis-a-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program Anticancer Drugs 13 2002 511 519
38. M. Alvarez, K. Paull, A. Monks, C. Hose, J.S. Lee, and J. Weinstein Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen J. Clin. Invest. 95 1995 2205 2214
39. F. Goldwasser, I. Bae, M. Valenti, K. Torres, and Y. Pommier Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen Cancer Res. 55 1995 2116 2121
40. M.I. Nicoletti, G. Valoti, P. Giannakakou, Z. Zhan, J.H. Kim, and V. Lucchini Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents Clin Cancer Res. 7 2001 2912 2922
41. E.S. Woo, A. Monks, S.C. Watkins, A.S. Wang, and J.S. Lazo Diversity of metallothionein content and subcellular localization in the National Cancer Institute tumor panel Cancer Chemother. Pharmacol. 41 1997 61 68
42. L.J. Yu, J. Matias, D.A. Scudiero, K.M. Hite, A. Monks, and E.A. Sausville P450 enzyme expression patterns in the NCI human tumor cell line panel Drug Metab Dispos. 29 2001 304 312
43. J.L. Grem, K.D. Danenberg, K. Behan, A. Parr, L. Young, and P.V. Danenberg Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen Clin Cancer Res. 7 2001 999 1009
44. M. Alvarez, R. Robey, V. Sandor, K. Nishiyama, Y. Matsumoto, and K. Paull Using the National Cancer Institute anticancer drug screen to assess the effect of MRP expression on drug sensitivity profiles Mol. Pharmacol. 54 1998 802 814
45. S.A. Amundson, T.G. Myers, D. Scudiero, S. Kitada, J.C. Reed, and A.J. Fornace Jr. An informatics approach identifying markers of chemosensitivity in human cancer cell lines Cancer Res. 60 2000 6101 6110
46. P. Taverna, L. Liu, A.J. Hanson, A. Monks, and S.L. Gerson Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen Cancer Chemother. Pharmacol. 46 2000 507 516
47. D.T. Ross, U. Scherf, M.B. Eisen, C.M. Perou, C. Rees, and P. Spellman Systematic variation in gene expression patterns in human cancer cell lines Nat. Genet. 24 2000 227 235
48. U. Scherf, D.T. Ross, M. Waltham, L.H. Smith, J.K. Lee, and L. Tanabe A gene expression database for the molecular pharmacology of cancer Nat. Genet. 24 2000 236 244
49. A.J. Butte, P. Tamayo, D. Slonim, T.R. Golub, and I.S. Kohane Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks Proc. Natl. Acad Sci. U.S.A. 97 2000 12182 12186
50. J.E. Staunton, D.K. Slonim, H.A. Coller, P. Tamayo, M.I. Angelo, and J. Park Chemosensitivity prediction by transcriptional profiling Proc. Natl. Acad Sci. U.S.A. 98 2001 10787 10792
51. L. Bao, T. Guo, and Z.R. Sun Mining functional relationships in feature subspaces from gene expression profiles and drug activity profiles FEBS Lett. 516 2002 113 118
52. L. Bao, and Z. Sun Identifying genes related to drug anticancer mechanisms using support vector machine FEBS Lett. 521 2002 109 114
53. O. Micheau, E. Solary, A. Hammann, and M.T. Dimanche-Boitrel Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs J. Biol. Chem. 274 1999 7987 7992
54. A. Vekris, D. Meynard, M.C. Haaz, M. Bayssas, J. Bonnet, and J. Robert Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research Cancer Res. 64 2004 356 362
55. P.E. Blower, C. Yang, M.A. Fligner, J.S. Verducci, L. Yu, S. Richman, and J.N. Weinstein Pharmacogenomic analyses: correlating molecular substructure classes with microarray gene expression data Pharmacogenom. J. 2 2002 259 271
56. A. Wallqvist, A.A. Rabow, R.H. Shoemaker, E.A. Sausville, and D.G. Covell Linking the growth inhibition response from the National Cancer Institute's anticancer screen to gene expression levels and other molecular target data Bioinformatics 19 2003 2212 2224
57. K.C. Li, and S. Yuan A functional genomic study on NCI's anticancer drug screen Pharmacogenom. J. 4 2004 127 135
58. S. Dan, T. Tsunoda, O. Kitahara, R. Yanagawa, H. Zembutsu, and T. Katagiri An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines Cancer Res. 62 2002 1139 1147
59. H. Zembutsu, Y. Ohnishi, T. Tsunoda, Y. Furukawa, T. Katagiri, and Y. Ueyama Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs Cancer Res. 62 2002 518 527
60. J.M. Mariadason, D. Arango, Q. Shi, A.J. Wilson, G.A. Corner, and C. Nicholas Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin Cancer Res. 63 2003 8791 8812
61. W.D. Stein, T. Litman, T. Fojo, and S.E. Bates A Serial Analysis of Gene Expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins Cancer Res. 64 2004 2805 2816
62. A. Wallqvist, A.A. Rabow, R.H. Shoemaker, E.A. Sausville, and D.G. Covell Establishing connections between microarray expression data and chemotherapeutic cancer pharmacology Mol. Cancer Ther. 1 2002 311 320
63. J.M. Brown, and B.G. Wouters Apoptosis, p53, and tumor cell sensitivity to anticancer agents Cancer Res. 59 1999 1391 1399
64. J.M. Brown NCI's anticancer drug screening program may not be selecting for clinically active compounds Oncol. Res. 9 1997 213 215
65. R. Valavaara Reliability of estrogen receptors in predicting response to antiestrogens Oncology (Huntingt) 11 Suppl 4 1997 14 18
66. C.K. Osborne Steroid hormone receptors in breast cancer management Breast Cancer Res. Treat. 51 1998 227 238
67. L.J. Goldstein, H. Galski, A. Fojo, M. Willingham, S.L. Lai, and A. Gazdar Expression of a multidrug resistance gene in human cancers J. Natl. Cancer Inst. 81 1989 116 124
68. H.S. Chan, P.S. Thorner, G. Haddad, and V. Ling Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood J. Clin. Oncol. 8 1990 689 704
69. B.J. Trock, F. Leonessa, and R. Clarke Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance J. Natl. Cancer Inst. 89 1997 917 931
70. J.A. Holmes, and R.R. West The effect of MDR-1 gene expression on outcome in acute myeloblastic leukaemia Br. J. Cancer 69 1994 382 384
71. J.P. Marie, S. Huet, A.M. Faussat, J.Y. Perrot, S. Chevillard, and V. Barbu Multicentric evaluation of the MDR phenotype in leukaemia. French Network of the Drug Resistance Intergroup, and Drug Resistance Network of Assistance Publique-Hopitaux de Paris Leukemia 11 1997 1086 1094
72. W.T. Beck, T.M. Grogan, C.L. Willman, C. Cordon-Cardo, D.M. Parham, and J.F. Kuttesch Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations Cancer Res. 56 1996 3010 3020
73. T. Litman, T.E. Druley, W.D. Stein, and S.E. Bates From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance Cell Mol. Life Sci. 58 2001 931 959
74. P. Borst, R. Evers, M. Kool, and J. Wijnholds A family of drug transporters: the multidrug resistance-associated proteins J. Natl. Cancer Inst. 92 2000 1295 1302
75. W.S. El-Deiry The role of p53 in chemosensitivity and radiosensitivity Oncogene 22 2003 7486 74895
76. S.W. Lowe, S. Bodis, A. McClatchey, L. Remington, H.E. Ruley, and D.E. Fisher p53 status and the efficacy of cancer therapy in vivo Science 266 1994 807 810
77. K.F. Pirollo, K.B. Bouker, and E.H. Chang Does p53 status influence tumor response to anticancer therapies? Anticancer Drugs 11 2000 419 432
78. A.F. Wahl, K.L. Donaldson, C. Fairchild, F.Y. Lee, S.A. Foster, and G.W. Demers Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis Nat. Med. 2 1996 72 79
79. M. Weller Predicting response to cancer chemotherapy: the role of p53 Cell Tissue Res. 292 1998 435 445
80. K.R. Brooks, K. To, M.B. Joshi, D.H. Conlon, J.E. Herndon II, T.A. D'Amico, and D.H. Harpole Jr. Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection Ann. Thorac Surg. 76 2003 187 193
81. V. Gregorc, V. Ludovini, L. Pistola, S. Darwish, I. Floriani, and G. Bellezza Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer Lung Cancer 39 2003 41 48
82. Y. Nakanishi, M. Kawasaki, F. Bai, K. Takayama, X.H. Pei, and K. Takano Expression of p53 and glutathione S-transferase π relates to clinical drug resistance in non-small cell lung cancer Oncology 57 1999 318 323
83. V. Rusch, D. Klimstra, E. Venkatraman, J. Oliver, N. Martini, and R. Gralla Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer Cancer Res. 55 1995 5038 5042
84. T.C. King, W. Akerley, A.C. Fan, T. Moore, S. Mangray, and M. Hsiu Chen p53 mutations do not predict response to paclitaxel in metastatic non-small cell lung carcinoma Cancer 89 2000 769 773
85. H. Safran, T. King, H. Choy, A. Gollerkeri, H. Kwakwa, and F. Lopez p53 mutations do not predict response to paclitaxel/radiation for non-small cell lung carcinoma Cancer 78 1996 1203 1210
86. E.A. Johnson, D.S. Klimstra, J.E. Herndon II, E. Catalano, G.P. Canellos, and S.L. Graziano Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer Cancer Investig. 20 2002 686 692
87. T. Harada, S. Ogura, K. Yamazaki, I. Kinoshita, T. Itoh, and H. Isobe Predictive value of expression of p53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers Cancer Sci. 94 2003 394 399
88. W.H. Wilson, J. Teruya-Feldstein, T. Fest, C. Harris, S.M. Steinberg, and E.S. Jaffe Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphoma Blood 89 1997 601 609
89. E. Rahko, G. Blanco, Y. Soini, R. Bloigu, and A. Jukkola A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients Eur. J. Cancer 39 2003 447 453
90. S. Geisler, P.E. Lonning, T. Aas, H. Johnsen, O. Fluge, and D.F. Haugen Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer Cancer Res. 61 2001 2505 2512
91. P.C. Clahsen, C.J. van de Velde, C. Duval, C. Pallud, A.M. Mandard, and A. Delobelle-Deroide p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer J. Clin. Oncol. 16 1998 470 479
92. A. Bottini, A. Berruti, A. Bersiga, M.P. Brizzi, A. Brunelli, and G. Gorzegno p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients Clin. Cancer Res. 6 2000 2751 2758
93. A. Faille, P. De Cremoux, J.M. Extra, G. Linares, M. Espie, and E. Bourstyn p53 mutations and overexpression in locally advanced breast cancers Br. J. Cancer 69 1994 1145 1150
94. S. Geisler, A.L. Borresen-Dale, H. Johnsen, T. Aas, J. Geisler, and L.A. Akslen TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer Clin. Cancer Res. 9 2003 5582 5588
95. A. Anelli, R.R. Brentani, A.P. Gadelha, A. Amorim De Albuquerque, and F. Soares Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer Ann. Oncol. 14 2003 428 432
96. M. Schmidt, A. Bachhuber, A. Victor, E. Steiner, M. Mahlke, and H.A. Lehr p53 expression and resistance against paclitaxel in patients with metastatic breast cancer J. Cancer Res. Clin. Oncol. 129 2003 295 302
97. D. Kandioler-Eckersberger, C. Ludwig, M. Rudas, S. Kappel, E. Janschek, and C. Wenzel TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients Clin. Cancer Res. 6 2000 50 56
98. P. Bertheau, F. Plassa, M. Espie, E. Turpin, A. de Roquancourt, and M. Marty Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy Lancet 360 2002 852 854
99. M. Colleoni, E. Orvieto, F. Nole, L. Orlando, I. Minchella, and G. Viale Prediction of response to primary chemotherapy for operable breast cancer Eur. J. Cancer 35 1999 574 579
100. A. Bonetti, M. Zaninelli, R. Leone, G.L. Cetto, G. Pelosi, and S. Biolo bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer Clin. Cancer Res. 4 1998 2331 2336
101. J. Sjostrom, C. Blomqvist, P. Heikkila, K.V. Boguslawski, A. Raisanen-Sokolowski, and N.O. Bengtsson Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer Clin. Cancer Res. 6 2000 3103 3110
102. A. Hamilton, D. Larsimont, R. Paridaens, M. Drijkoningen, M. van de Vijver, and P. Bruning A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923 Clin. Breast Cancer 1 2000 233 240
103. J. Benhattar, J.P. Cerottini, E. Saraga, G. Metthez, and J.C. Givel p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas Int. J. Cancer 69 1996 190 192
104. J.T. Liang, K.C. Huang, Y.M. Cheng, H.C. Hsu, A.L. Cheng, and C.H. Hsu P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection Int. J. Cancer 97 2002 451 457
105. H. Elsaleh, B. Powell, K. McCaul, F. Grieu, R. Grant, and D. Joseph p53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma Clin. Cancer Res. 7 2001 1343 1349
106. S. Kikuyama, T. Inada, K. Shimizu, M. Miyakita, and Y. Ogata p53, bcl-2 and thymidine phosphorylase as predictive markers of chemotherapy in patients with advanced and recurrent gastric cancer Anticancer Res. 21 2001 2149 2153
107. A. Paradiso, M. Rabinovich, C. Vallejo, M. Machiavelli, A. Romero, and J. Perez p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long-term prognosis Int. J. Cancer 69 1996 437 441
108. H.S. Goh, J. Yao, and D.R. Smith p53 mutation and survival in colorectal cancer patients Cancer Res. 55 1995 5217 5221
109. D.J. Ahnen, P. Feigl, G. Quan, C. Fenoglio-Preiser, L.C. Lovato, and P.A. Bunn Jr. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer. A Southwest Oncology Group Study Cancer Res. 58 1998 1149 1158
110. S. Cascinu, V. Catalano, C. Aschele, S. Barni, D. Debernardis, and L. Gallo Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination Ann. Oncol. 11 2000
111. P.G. Johnston, N. Wolmark, and H.S. Wieand Prognostic value of thymidylate synthase, Ki-67 and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute - National Surgical Breast and Bowel Project cooperative study J. Clin. Oncol. 21 2003 241 250
112. A.F. Logullo, R.P. de Moura, S. Nonogaki, L.P. Kowalski, M.A. Nagai, and A.J. Simpson A proposal for the integration of immunohistochemical staining and DNA-based techniques for the determination of TP53 mutations in human carcinomas Diagn. Mol. Pathol. 9 2000 35 40
113. J. Bénard, and J.C. Ahomadegbe p53 status and response to chemotherapy Bull. Cancer 89 2002 1007 1010
114. W. Dietmaier, S. Wallinger, T. Bocker, F. Kullmann, R. Fishel, and J. Ruschoff Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression Cancer Res. 57 1997 4749 4756
115. H.S. Friedman, S.P. Johnson, Q. Dong, S.C. Schold, B.K. Rasheed, and S.H. Bigner Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft Cancer Res. 57 1997 2933 2936
116. D. Fink, S. Nebel, S. Aebi, H. Zheng, B. Cenni, and A. Nehme The role of DNA mismatch repair in platinum drug resistance Cancer Res. 56 1996 4881 4886
117. A. Fedier, V.A. Schwarz, H. Walt, R.D. Carpini, U. Haller, and D. Fink Resistance to topoisomerase poisons due to loss of DNA mismatch repair Int. J. Cancer 93 2001 571 576
118. D.A. Anthoney, A.J. McIlwrath, W.M. Gallagher, A.R. Edlin, and R. Brown Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells Cancer Res. 56 1996 1374 1381
119. M. Meyers, M.W. Wagner, H.S. Hwang, T.J. Kinsella, and D.A. Boothman Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses Cancer Res. 61 2001 5193 5201
120. J.M. Carethers, D.P. Chauhan, D. Fink, S. Nebel, R.S. Bresalier, and S.B. Howell Mismatch repair proficiency and in vitro response to 5-fluorouracil Gastroenterology 117 1999 123 131
121. C. Rosty, M. Chazal, M.C. Etienne, C. Letoublon, A. Bourgeon, and J.R. Delpero Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival Int. J. Cancer 95 2001 162 167
122. A. Hemmincki, J.P. Mecklin, H. Jarvinen, L.A. Aaltonen, and H. Joensuu Microsatellite instability is a favourable prognostic indicator in patients with colorectal cancer receiving chemotherapy Gastroenterology 119 2000 921 928
123. H. Elsaleh, D. Joseph, F. Grieu, N. Zeps, N. Spry, and B. Iacopetta Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer Lancet 355 2000 1745 1750
124. C.M. Ribic, D.J. Sargent, M.J. Moore, S.N. Thibodeau, A.J. French, and R.M. Goldberg Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer N. Engl. J. Med. 349 2003 247 257
125. D. Fallik, F. Borrini, V. Boige, J. Viguier, S. Jacob, and C. Miquel Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer Cancer Res. 63 2003 5738 5744
126. R.A. Bras-Goncalves, C. Rosty, P. Laurent-Puig, P. Soulie, B. Dutrillaux, and M.F. Poupon Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status Br. J. Cancer 82 2000 913 923
127. 6- alkylguanine Faseb J. 6 1992 2302 2310
128. 6-methylguanine DNA-methyltransferase expression J. Pharmacol. Exp. Ther. 307 2003 816 823
129. 6-alkylguanine-DNA-alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma J. Clin. Oncol. 16 1998 3851 3857
130. 6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma Br. J. Cancer 89 2003 1517 1523
131. M. Esteller, J. Garcia-Foncillas, E. Andion, S.N. Goodman, O.F. Hidalgo, and V. Vanaclocha Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N. Engl. J. Med. 343 2000 1350 1354
132. 6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study J. Clin. Oncol. 16 1998 3310 3315
133. 6-methylguanine-DNA-methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma Br. J. Cancer 78 1998 1199 1202
134. 6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy Clin. Cancer Res. 5 1999 807 814
135. S.G. Chaney, and A. Sancar DNA repair: enzymatic mechanisms and relevance to drug response J. Natl. Cancer Inst. 88 1996 1346 1360
136. M. Dabholkar, F. Bostick-Bruton, C. Weber, V.A. Bohr, C. Egwuagu, and E. Reed ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients J. Natl. Cancer Inst. 84 1992 1512 1517
137. Y. Shirota, J. Stoehlmacher, J. Brabender, Y.P. Xiong, H. Uetake, and K.D. Danenberg ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy J. Clin. Oncol. 19 2001 4298 4304
138. R.V. Lord, J. Brabender, D. Gandara, V. Alberola, C. Camps, and M. Domine Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer Clin. Cancer Res. 8 2002 2286 2291
139. Y. Takebayashi, P. Pourquier, D.B. Zimonjic, K. Nakayama, S. Emmert, and T. Ueda Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair Nat. Med. 7 2001 961 966
140. Z.M. Wang, Z.P. Chen, Z.Y. Xu, G. Christodoulopoulos, V. Bello, and G. Mohr In vitro evidence for homologous recombinational repair in resistance to melphalan J. Natl. Cancer Inst. 93 2001 1473 1478
141. S.H. Berger, C.H. Jenh, L.F. Johnson, and F.G. Berger Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells Mol. Pharmacol. 28 1985 461 467
142. P.G. Johnston, H.J. Lenz, C.G. Leichman, K.D. Danenberg, C.J. Allegra, and P.V. Danenberg Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors Cancer Res. 55 1995 1407 1412
143. C.G. Leichman, H.J. Lenz, L. Leichman, K. Danenberg, J. Baranda, and S. Groshen Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin J. Clin. Oncol. 15 1997 3223 3229
144. H.J. Lenz, K. Hayashi, D. Salonga, K.D. Danenberg, P.V. Danenberg, and R. Metzger p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival Clin. Cancer Res. 4 1998 1243 1250
145. T. Yamachika, H. Nakanishi, K. Inada, T. Tsukamoto, T. Kato, and M. Fukushima A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance Cancer 82 1998 70 77
146. C. Aschele, D. Debernardis, S. Casazza, G. Antonelli, G. Tunesi, and C. Baldo Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy J. Clin. Oncol. 17 1999 1760 1770
147. S. Cascinu, C. Aschele, S. Barni, D. Debernardis, C. Baldo, and G. Tunesi Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil Clin. Cancer Res. 5 1999 1996 1999
148. D. Salonga, K.D. Danenberg, M. Johnson, R. Metzger, S. Groshen, and D.D. Tsao-Wei Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase Clin. Cancer Res. 6 2000 1322 1327
149. B. van Triest, H.M. Pinedo, J.L. Blaauwgeers, P.J. van Diest, P.S. Schoenmakers, and D.A. Voorn Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer Clin. Cancer Res. 6 2000 1063 1072
150. N.A. Wong, L. Brett, M. Stewart, A. Leitch, D.B. Longley, and M.G. Dunlop Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma Br. J. Cancer 85 2001 1937 1943
151. M.C. Etienne, M. Chazal, P. Laurent-Puig, N. Magne, C. Rosty, and J.L. Formento Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses J. Clin. Oncol. 20 2002 2832 2843
152. M. Kornmann, W. Schwabe, S. Sander, M. Kron, J. Strater, and S. Polat Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil Clin. Cancer Res. 9 2003 4116 4124
153. D. Edler, U. Kressner, P. Ragnhammar, P.G. Johnston, I. Magnusson, and B. Glimelius Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival Clin Cancer Res. 6 2000 488 492
154. D. Edler, B. Glimelius, M. Hallstrom, A. Jakobsen, P.G. Johnston, and I. Magnusson Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy J. Clin. Oncol. 20 2002 1721 1728
155. A. Paradiso, G. Simone, S. Petroni, B. Leone, C. Vallejo, and J. Lacava Thymidylate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients Br. J. Cancer 82 2000 560 567
156. C. Aschele, D. Debernardis, G. Tunesi, F. Maley, and A. Sobrero Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil Clin. Cancer Res. 6 2000 4797 4802
157. P.G. Johnston, A.B. Benson III, P. Catalano, M.S. Rao, P.J. O'Dwyer, and C.J. Allegra Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites J. Clin. Oncol. 21 2003 815 819
158. J.R. Bertino, and D. Banerjee Is the measurement of thymidylate synthase to determine suitability for treatment with 5-fluoropyrimidines ready for prime time? Clin. Cancer Res. 9 2003 1235 1239
159. S. Popat, A. Matakidou, and R.S. Houlston Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis J. Clin. Oncol. 22 2004 529 536
160. K.H. Link, M. Kornmann, U. Butzer, G. Leder, E. Sunelaitis, and J. Pillasch Thymidylate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapy Cancer 89 2000 288 296
161. Y.C. Hu, R.A. Komorowski, S. Graewin, G. Hostetter, O.P. Kallioniemi, and H.A. Pitt Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer Clin. Cancer Res. 9 2003 4165 4171
162. M. Gonen, A. Hummer, A. Zervoudakis, D. Sullivan, Y. Fong, and D. Banerjee Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer J. Clin. Oncol. 21 2003 406 412
163. Y. Pommier, P. Pourquier, Y. Urasaki, J. Wu, and G.S. Laco Topoisomerase I inhibitors: selectivity and cellular resistance Drug Resist. Updat. 2 1999 307 318
164. J. Robert, and A.K. Larsen Drug resistance to topoisomerase II inhibitors Biochimie 80 1998 247 254
165. B.C. Giovanella, J.S. Stehlin, M.E. Wall, M.C. Wani, A.W. Nicholas, and L.F. Liu DNA topoisomerase I targeted chemotherapy of human colon cancer in xenografts Science 246 1989 1046 1048
166. W.J.M. Jansen, B. Zwart, Hulscher STM, G. Giaccone, H.M. Pinedo, and E. Boven CPT-11 in human colon cancer cell lines and xenografts: characterization of cellular sensitivity determinants Int. J. Cancer 70 1997 335 340
167. I. Husain, J.L. Mohler, H.F. Seigler, and J.M. Besterman Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy Cancer Res. 54 1994 539 546
168. G. MacGrogan, P. Rudolph, I. de Mascarel, L. Mauriac, M. Durand, and A. Avril DNA topoisomerase II alpha expression and the response to primary chemotherapy in breast cancer Br. J. Cancer 89 2003 666 671
169. J.P. Braybrooke, N.C. Levitt, S. Joel, T. Davis, S. Madhusudan, and H. Turley Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIα expression Clin. Cancer Res. 9 2003 4682 4688
170. T.A. Jarvinen, K. Holli, T. Kuukasjarvi, and J.J. Isola Predictive value of topoisomerase II alpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer Br. J. Cancer 77 1998 2267 2273
171. M. Provencio, C. Corbacho, C. Salas, I. Millan, P. Espana, and F. Bonilla The topoisomerase IIα expression correlates with survival in patients with advanced Hodgkin's lymphoma Clin. Cancer Res. 9 2003 1406 1411
172. A.M. Dingemans, M.A. Witlox, R.A. Stallaert, P. van der Valk, P.E. Postmus, and G. Giaccone Expression of DNA topoisomerase IIα and topoisomerase IIβ genes predicts survival and response to chemotherapy in patients with small cell lung cancer Clin. Cancer Res. 5 1999 2048 2058
173. C.A. Burkhart, M. Kavallaris, and S.B. Horwitz The role of β-tubulin isotypes in resistance to antimitotic drugs Biochim. Biophys. Acta 1471 2001 O1 9
174. M. Kavallaris, D.Y. Kuo, C.A. Burkhart, D.L. Regl, M.D. Norris, and M. Haber Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes J. Clin. Invest. 100 1997 1282 1293
175. S. Hasegawa, Y. Miyoshi, C. Egawa, M. Ishitobi, T. Taguchi, and Y. Tamaki Prediction of response to docetaxel by quantitative analysis of class I and III β-tubulin isotype mRNA expression in human breast cancers Clin. Cancer Res. 9 2003 2992 2997
176. R. Rosell, G. Scagliotti, K.D. Danenberg, R.V. Lord, G. Bepler, and S. Novello Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer Oncogene 22 2003 3548 3553
177. L.K. Mattison, R. Soong, and R.B. Diasio Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics Pharmacogenomics 3 2002 485 492
178. M.C. Etienne, S. Cheradame, J.L. Fischel, P. Formento, O. Dassonville, and N. Renee Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity J. Clin. Oncol. 13 1995 1663 1670
179. W. Ichikawa, H. Uetake, Y. Shirota, H. Yamada, N. Nishi, Z. Nihei, and K. Sugihara Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer Clin. Cancer Res. 9 2003 786 791
180. H. Saito, S. Tsujitani, S. Oka, A. Kondo, M. Ikeguchi, and M. Maeta The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma Br. J. Cancer 81 1999 484 489
181. R. Metzger, K. Danenberg, C.G. Leichman, D. Salonga, E.L. Schwartz, and S. Wadler High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil Clin. Cancer Res. 4 1998 2371 2376
182. K.D. Tew Glutathione-associated enzymes in anticancer drug resistance Cancer Res. 54 1994 4313 4320
183. K.J. Cullen, K.A. Newkirk, L.M. Schumaker, N. Aldosari, J.D. Rone, and B.R. Haddad Glutathione S-transferase π amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors Cancer Res. 63 2003 8097 9102
184. F. Su, X. Hu, W. Jia, C. Gong, E. Song, and P. Hamar Glutathion S-transferase π indicates chemotherapy resistance in breast cancer J. Surg. Res. 113 2003 102 108
185. C.A. Schmitt, and S.W. Lowe Apoptosis is critical for drug response in vivo Drug Resist. Updat. 4 2001 132 134
186. I.F. Tannock, and C. Lee Evidence against apoptosis as a major mechanism for reproductive cell death following treatment of cell lines with anti-cancer drugs Br. J. Cancer 84 2001 100 105
187. U.A. Sartorius, and P.H. Krammer Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines Int. J. Cancer 97 2002 584 592
188. L. Campos, J.P. Rouault, O. Sabido, P. Oriol, N. Roubi, and C. Vasselon High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy Blood 81 1993 3091 3096
189. Z.T. Maung, F.R. MacLean, M.M. Reid, A.D. Pearson, S.J. Proctor, and P.J. Hamilton The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia Br. J. Haematol. 88 1994 105 109
190. T. Karakas, C.C. Miething, U. Maurer, E. Weidmann, H. Ackermann, and D. Hoelzer The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia Leukemia 16 2002 846 854
191. H.J. van Slooten, P.C. Clahsen, J.H. van Dierendonck, C. Duval, C. Pallud, and A.M. Mandard Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy Br. J. Cancer 74 1996 78 85
192. S.M. Poelman, M.O. Adeyanju, M.A. Robertson, W.M. Recant, T. Karrison, and G.F. Fleming Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression Clin. Cancer Res. 6 2000 4043 4048
193. J. Sjostrom, C. Blomqvist, K. von Boguslawski, N.O. Bengtsson, I. Mjaaland, and P. Malmstrom The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer Clin. Cancer Res. 8 2002 811 816
194. H.J. Schneider, S.A. Sampson, D. Cunningham, A.R. Norman, H.J. Andreyev, and J.V. Tilsed Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas Br. J. Cancer 75 1997 427 431
195. T. Harada, S. Ogura, K. Yamazaki, I. Kinoshita, T. Itoh, and H. Isobe Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers Cancer Sci. 94 2003 394 399
196. S. Kitada, J. Andersen, S. Akar, J.M. Zapata, S. Takayama, and S. Krajewski Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses Blood 91 1998 3379 3389
197. A. Saxena, S. Viswanathan, O. Moshynska, P. Tandon, K. Sankaran, and D.P. Sheridan Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia Am. J. Hematol. 75 2004 22 33
198. J. Sjostrom, S. Krajewski, K. Franssila, E. Niskanen, V.M. Wasenius, and S. Nordling A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer Br. J. Cancer 78 1998 812 815
199. S. Krajewski, C. Blomqvist, K. Franssila, M. Krajewska, V.M. Wasenius, and E. Niskanen Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma Cancer Res. 55 1995 4471 4478
200. N. Zaffaroni, M. Pennati, G. Colella, P. Perego, R. Supino, and L. Gatti Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer Cell Mol. Life Sci. 59 2002 1406 1412
201. S.C. Formenti, D. Spicer, K. Skinner, D. Cohen, S. Groshen, and A. Bettini Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer Int. J. Radiat. Oncol. Biol. Phys. 52 2002 397 405
202. M. Campiglio, G. Somenzi, C. Olgiati, G. Beretta, A. Balsari, and N. Zaffaroni Role of proliferation in HER2 status predicted response to doxorubicin Int. J. Cancer 105 2003 568 573
203. T.A. Jarvinen, M. Tanner, V. Rantanen, M. Barlund, A. Borg, and S. Grenman Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer Am. J. Pathol. 156 2000 839 847
204. C. Egawa, K. Motomura, Y. Miyoshi, Y. Takamura, T. Taguchi, and Y. Tamaki Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers Breast Cancer Res. Treat. 78 2003 45 50
205. C. Egawa, Y. Miyoshi, Y. Takamura, T. Taguchi, Y. Tamaki, and S. Noguchi Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer Int. J. Cancer 95 2001 255 259
206. J. Brabender, K.D. Danenberg, R. Metzger, P.M. Schneider, J. Park, and D. Salonga Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival Clin. Cancer Res. 7 2001 1850 1855
207. L.H. Augenlicht, S. Wadler, G. Corner, C. Richards, L. Ryan, and A.S. Multani Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial Cancer Res. 57 1997 1769 1775
208. J. Seoane, H.V. Le, and J. Massague Myc suppression of the p21cip1 CDK inhibitor influences the outcome of the p53 response to DNA damge Nature 419 2002 729 734
209. D.R. Spigel, and H.J. Burstein Trastuzumab regimens for HER2-overexpressing metastatic breast cancer Clin. Breast Cancer 4 2003 329 337
210. J. Mendelsohn, and J. Baselga Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J. Clin. Oncol. 21 2003 2787 2799
211. M. West, C. Blanchette, and H. Dressman Predicting the clinical status of human breast cancer by using gene expression profiles Proc. Natl. Acad Sci. U.S.A. 98 2001 11462 11467
212. L.J. Van't Veer, H. Dai, M.J. van de Vijver, Y.D. He, A.A. Hart, and M. Mao Gene expression profiling predicts clinical outcome of breast cancer Nature 415 2002 530 536
213. A. Rosenwald, G. Wright, W.C. Chan, J.M. Connors, E. Campo, and R.I. Fisher Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma N. Engl. J. Med. 346 2002 1937 1947
214. M.A. Shipp, K.N. Ross, P. Tamayo, A.P. Weng, J.L. Kutok, and R.C. Aguiar Diffuse large B-cell lymhoma outcome prediction by gene expression profiling and supervised machine learning Nat. Med. 8 2002 68 74
215. J. Okutsu, T. Tsunoda, Y. Kaneta, T. Katagiri, O. Kitahara, and H. Zembutsu Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis Mol. Cancer Ther. 1 2002 1035 1042
216. T. Kikuchi, Y. Daigo, T. Katagiri, T. Tsunoda, K. Okada, and S. Kakiuchi Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs Oncogene 22 2003 2192 2205
217. O. Kitahara, T. Katagiri, T. Tsunoda, Y. Harima, and Y. Nakamura Classification of sensitivity or resistance of cervical cancers to ionizing radiation according to expression profiles of 62 genes selected by cDNA microarray analysis Neoplasia 4 2002 295 303
218. C. Kihara, T. Tsunoda, T. Tanaka, H. Yamana, Y. Furukawa, and K. Ono Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene expression profiles Cancer Res. 61 2001 6474 6479
219. J.C. Chang, E.C. Wooten, A. Tsimelzon, S.G. Hilsenbeck, M.C. Gutierrez, and R. Elledge Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer Lancet 362 2003 362 369
220. M. Ayers, W.F. Symmans, J. Stec, A.I. Damokosh, E. Clark, and K. Hess Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer J. Clin. Oncol. 22 2004 2284 2293
221. E.E. Ntzani, and J.P. Ioannidis Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment Lancet 362 2003 1439 1444